Author: admin

“Delveinsight Business Research LLP”

DelveInsight’s “Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pyelonephritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Pyelonephritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Pyelonephritis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Pyelonephritis: An Overview

According to the National Institute of Diabetes and Digestive and Kidney Diseases, Pyelonephritis (Kidney infection) is an infection of the kidney that most often occurs when a urinary tract infection spreads beyond the bladder to the ureters and kidneys.

The most common cause of the disease is bacterial infection, and based on the severity it is classified into acute and chronic pyelonephritis. The main cause of acute pyelonephritis is gram-negative bacteria, the most common being Escherichia coli. Other gram-negative bacteria that cause acute pyelonephritis include Proteus, Klebsiella, and Enterobacter. Acute pyelonephritis can be further subdivided into uncomplicated and complicated pyelonephritis.

Reflux-associated chronic pyelonephritis is the most common form and occurs when there is a reflux of urine from the bladder, resulting in kidney scarring. Obstructive chronic pyelonephritis occurs from recurrent episodes of kidney infection that result from distal obstruction. The common symptoms of pyelonephritis are fever, chills, cloudy dark bloody, or foul-smelling urine, frequent and painful urination, nausea, and vomiting.

Pyelonephritis Market Key Facts

• A population-based study of acute pyelonephritis (APN) in the United States found overall annual rates of 15–17 cases per 10,000 females and 3–4 cases per 10,000 males (Czaja, Scholes, Hooton, & Stamm, 2007).

• Approximately 20–35% of females experience an episode of APN in their lifetime (Clementi, 2015). 

• An estimated one in 830 people in the UK experience pyelonephritis every year, and females are six times more likely to experience the infection than males.

• According to a Japanese study, pyelonephritis is one of the causes of end-stage renal disease (ESRD), and among all the major causes of ESRD, age-adjusted incidence rates for men have always been higher than those for women. However, the sex ratio was relatively low for pyelonephritis, averaging to be 1.07 (Wakai et al., 2004).

Pyelonephritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Pyelonephritis pipeline therapies. It also thoroughly assesses the Pyelonephritis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Pyelonephritis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Pyelonephritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Pyelonephritis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Pyelonephritis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Pyelonephritis Epidemiology, Segmented as –

• Total Incidence of Pyelonephritis in the 7MM (2019–2032)

• Gender-specific Incidence of Pyelonephritis in the 7MM (2019–2032)

• Treatable Cases of Pyelonephritis in the 7MM (2019-2032)

• Incidence of Pyelonephritis by Causative Agents (E. coli, Enterobacteriaceae, Pseudomonas aeruginosa, and others) in the 7MM (2019–2032)

Pyelonephritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pyelonephritis market or expected to be launched during the study period. The analysis covers the Pyelonephritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Pyelonephritis drugs based on their sale and market share.

The report also covers the Pyelonephritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Pyelonephritis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Pyelonephritis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

Pyelonephritis Therapeutics Analysis

Pyelonephritis is a type of urinary tract infection that commonly begins in the bladder and moves upstream to one or both of the kidneys. In rare cases, kidney infections can lead to serious health problems, but quick treatment prevents most complications.

Antimicrobial agents are useful for the treatment of pyelonephritis. Antimicrobial selection and route of administration are guided by local microbial resistance patterns and the ability of the patient to take and retain oral agents. Children who are suspected of having pyelonephritis are started empirically on antibiotics effective against the usual pathogens for their clinical condition.

Oral drugs such as fluoroquinolones (ciprofloxacin (Cipro), and moxifloxacin), trimethoprim-sulfamethoxazole (TMP-SMX/Bactrim and others), amoxicillin, ampicillin, sulfonamides, and nitrofurantoin are useful in the management of pyelonephritis. Parenteral doses of the ceftriaxone, fluoroquinolones, gentamicin, and aztreonam are also used.

In November 2019, the US FDA approved Fetroja (cefiderocol), an antibacterial drug for the treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex, in patients 18 years of age or older who have limited or no alternative treatment options.

Several major pharma and biotech companies are actively engaged in developing therapies for Pyelonephritis. Notably, Wockhardt stands out among them, with Pyelonephritis drug candidates advancing to the most advanced stage, specifically Phase III of clinical trials. This underscores the commitment of these companies to advancing potential treatments for Pyelonephritis, with Wockhardt leading the way in the progression of clinical development for this medical condition.

Pyelonephritis Companies Actively Working in the Therapeutics Market Include

• Wockhardt

• Sinovent

• EntasisTherapeutics

• MelintaTherapeutics

• Spero Therapeutics

• Allecra Therapeutics

• VenatoRx Pharmaceuticals

• Nabriva Therapeutics

And Many Others

Emerging and Marketed Pyelonephritis Therapies Covered in the Report Include:

• WCK-5222: Wockhardt

• XNW 4107: Sinovent

• ETX2514SUL: Entasis Therapeutics

• Contepo: Nabriva Therapeutics

• Tebipenem HBr (SPR994): Spero Therapeutics

• Cefepime-Enmetazobactam/AAI101: Allecra Therapeutics

• Cefepime/taniborbactam: VenatoRx Pharmaceuticals

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Pyelonephritis Competitive Intelligence Analysis

4. Pyelonephritis Market Overview at a Glance

5. Pyelonephritis Disease Background and Overview

6. Pyelonephritis Patient Journey

7. Pyelonephritis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Pyelonephritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Pyelonephritis Unmet Needs

10. Key Endpoints of Pyelonephritis Treatment

11. Pyelonephritis Marketed Therapies

12. Pyelonephritis Emerging Drugs and Latest Therapeutic Advances

13. Pyelonephritis Seven Major Market Analysis

14. Attribute Analysis

15. Pyelonephritis Market Outlook (In US, EU5, and Japan)

16. Pyelonephritis Companies Active in the Market

17. Pyelonephritis Access and Reimbursement Overview

18. KOL Views on the Pyelonephritis Market

19. Pyelonephritis Market Drivers

20. Pyelonephritis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hepatorenal Syndrome Market

“Hepatorenal Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hepatorenal Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hepatorenal Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pyelonephritis Market Anticipates Impressive Growth Trajectory Through 2032 – Asserts DelveInsight | Wockhardt, Sinovent, Entasis, MelintaTherapeutics, Spero Therapeutics, Allecra, VenatoRx, Nabriva

“Delveinsight Business Research LLP”

DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Neuromyelitis Optica Spectrum Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Neuromyelitis Optica Spectrum Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Neuromyelitis Optica Spectrum Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Neuromyelitis Optica Spectrum Disorder (NMOSD): An Overview

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying the current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months, or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).

Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which is present in 50% of cases. NMOSD is regarded as an autoimmune disease, though the exact cause of the autoimmunity is unknown.

For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not respond to intravenous corticosteroids. For long-term suppression of the disease, a variety of immunosuppressive drugs are regarded by many clinicians as first-line therapy Symptom treatment may also involve the use of low doses of carbamazepine to control paroxysmal (sudden) tonic spasms that often occur during attacks of NMOSD and antispasticity agents to treat long term complication of spasticity that frequently develops in those with permanent motor deficits.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Key Facts

• According to the Orphanet, NMO has a worldwide distribution and estimated prevalence of 1-2/100,000. 

• According to the “National Organization for Rare Disorders”, The prevalence of NMOSD is approximately 1-10 per 100,000 individuals and seems to be similar worldwide, although somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry.

• As per the National Organization for Rare Disorders, Individuals of any age may be affected,

• but typically NMOSD, especially cases seropositive for AQP4-IgG, occurs in late middle-aged women. Women, especially those with AQP4-IgG, are four or five times more likely to be affected than men by the recurring (relapsing) form.

• According to the “Siegel Rare Neuroimmune Association”, NMOSD can affect children as young as 3 years and adults as old as 90 years. The onset of NMOSD varies from childhood to adulthood, and the average age of onset is about 40.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Neuromyelitis Optica Spectrum Disorder pipeline therapies. It also thoroughly assesses the Neuromyelitis Optica Spectrum Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Neuromyelitis Optica Spectrum Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Neuromyelitis Optica Spectrum Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Neuromyelitis Optica Spectrum Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology, Segmented as –

• Total Prevalent Cases of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032)

• Gender-specific Prevalence of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032)

• Age-specific Prevalence of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032)

• Diagnosed Cases of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032)

• NMO-IgG Diagnosed Cases of Neuromyelitis Optica Spectrum Disorder in 7MM (2019–2032)

Neuromyelitis Optica Spectrum Disorder Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Neuromyelitis Optica Spectrum Disorder market or expected to be launched during the study period. The analysis covers the Neuromyelitis Optica Spectrum Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Neuromyelitis Optica Spectrum Disorder drugs based on their sale and market share.

The report also covers the Neuromyelitis Optica Spectrum Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Neuromyelitis Optica Spectrum Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Neuromyelitis Optica Spectrum Disorder Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Analysis

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion. Treatment of NMO includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Preventative therapy should lower the frequency and severity of future exacerbations.

Several major pharma and biotech companies are actively involved in developing therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD). Notably, RemeGen stands out among them, with NMOSD drug candidates progressing to the most advanced stage, specifically phase III of clinical trials. This highlights the dedication of these companies to advancing potential treatments for NMOSD, with RemeGen at the forefront of clinical development in addressing this neurological disorder.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Actively Working in the Therapeutics Market Include

Some of the major pharma and biotech giants such as RemeGen, Alexion Pharmaceuticals, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, NovelMed, and others are actively working in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market. 

Emerging and Marketed Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapies Covered in the Report Include:

• Telitacicept: RemeGen

• Ravulizumab: Alexion Pharmaceuticals

• SHR1459: Reistone Biopharma

• BAT4406F: Bio-Thera Solutions

• HBM9161: Harbour BioMed

• ARN-6039: Boston Pharmaceuticals

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Neuromyelitis Optica Spectrum Disorder Competitive Intelligence Analysis

4. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance

5. Neuromyelitis Optica Spectrum Disorder Disease Background and Overview

6. Neuromyelitis Optica Spectrum Disorder Patient Journey

7. Neuromyelitis Optica Spectrum Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Neuromyelitis Optica Spectrum Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Neuromyelitis Optica Spectrum Disorder Unmet Needs

10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment

11. Neuromyelitis Optica Spectrum Disorder Marketed Therapies

12. Neuromyelitis Optica Spectrum Disorder Emerging Drugs and Latest Therapeutic Advances

13. Neuromyelitis Optica Spectrum Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Neuromyelitis Optica Spectrum Disorder Market Outlook (In US, EU5, and Japan)

16. Neuromyelitis Optica Spectrum Disorder Companies Active in the Market

17. Neuromyelitis Optica Spectrum Disorder Access and Reimbursement Overview

18. KOL Views on the Neuromyelitis Optica Spectrum Disorder Market

19. Neuromyelitis Optica Spectrum Disorder Market Drivers

20. Neuromyelitis Optica Spectrum Disorder Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Choroideremia Market

“Choroideremia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Choroideremia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Choroideremia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuromyelitis Optica Spectrum Disorder (NMOSD) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | RemeGen, Alexion, Bionure, ENDECE, NovelMed

“Delveinsight Business Research LLP”

DelveInsight’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Inflammatory Demyelinating Polyneuropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Chronic Inflammatory Demyelinating Polyneuropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chronic Inflammatory Demyelinating Polyneuropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath of the peripheral nerves. It is an acquired peripheral neuropathy due to an autoimmune attack of peripheral nerve myelin. Myelin is the main target of the condition, in which patients present with weakness, numbness, and sensory ataxia.

Although the precise origin of CIDP is uncertain, there are several signs that suggest it is an autoimmune condition. When the body’s natural defenses (antibodies and lymphocytes) against invading pathogens suddenly start attacking perfectly healthy tissue, it results in autoimmune diseases. Recent research has identified antibodies that induce uncommon forms of CIDP (neurofascin 155 and contactin 1) by attacking peripheral nerve components.

The progression of CIDP varies greatly from patient to patient. Some patients may experience a CIDP episode followed by spontaneous recovery, while others may experience several episodes with partial recovery in between relapses. It is advised to begin therapy as soon as possible to avoid the loss of nerve axons since the condition is a curable cause of acquired neuropathy. Prednisone and other corticosteroids are used to treat CIDP, either alone or in conjunction with immunosuppressant medications. The use of intravenous immunoglobulin (IVIg) and plasmapheresis (plasma exchange) is successful.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Key Facts

• The total CIDP prevalent population in the 7MM was 45,200+ in 2019 and is expected to rise by 2032.

• As per the estimate, the United States accounts for the highest cases (approximately 65%) of total CIDP cases as compared to EU5, and Japan.

• The overall prevalence of typical CIDP was higher as compared to atypical CIDP and is subject to increase rapidly in the coming years. In 2019, prevalent cases of typical and atypical CIDP in the US varied from 11,500+ and 10,900+ respectively.

• Among the European 5 countries, France had the highest CIDP prevalent population with 3,800 cases, followed by Germany and the UK. On the other hand, Spain had the lowest prevalent CIDP population of 1,900 in 2019.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chronic Inflammatory Demyelinating Polyneuropathy pipeline therapies. It also thoroughly assesses the Chronic Inflammatory Demyelinating Polyneuropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Chronic Inflammatory Demyelinating Polyneuropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Epidemiology, Segmented as –

• Total Prevalent Pool of CIDP

• Gender-specific Prevalent Pool of CIDP

• Clinical Subtype-based (Typical/Atypical) 

• Diagnosed Prevalent Pool of CIDP

• Age-specific Prevalent Pool of CIDP

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chronic Inflammatory Demyelinating Polyneuropathy market or expected to be launched during the study period. The analysis covers the Chronic Inflammatory Demyelinating Polyneuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chronic Inflammatory Demyelinating Polyneuropathy drugs based on their sale and market share.

The report also covers the Chronic Inflammatory Demyelinating Polyneuropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chronic Inflammatory Demyelinating Polyneuropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Chronic Inflammatory Demyelinating Polyneuropathy Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Analysis

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare, treatable, peripheral nerve disorder of an autoimmune basis. The primary goal of CIDP treatment is to reduce symptoms of weakness, sensory loss, imbalance, and pain along with improving functional status (such as reducing disability and handicap).

The current treatments used on patients with CIDP have some limitations because they are expensive, it is challenging to find the right therapeutic window to balance effectiveness with adverse events (AEs) when using corticoids and immunosuppressive agents, the disease itself is heterogeneous, and some patients are resistant to common medications or develop non-responders over time. Therefore, there is a huge unmet need in the CIDP for drug development.

Several major pharma and biotech companies are actively involved in developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy. Notably, Takeda stands out among them, with Chronic Inflammatory Demyelinating Polyneuropathy drug candidates advancing to the most advanced stage, specifically phase III of clinical trials. 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Actively Working in the Therapeutics Market Include

Some of the key companies in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market include Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO Biotherapeutics, Bioasis Technologies, Inc., CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, UCB Biopharma, MedDay Pharmaceuticals, Pfizer, Argenx, Momenta Pharmaceuticals, and many others.

Emerging and Marketed Chronic Inflammatory Demyelinating Polyneuropathy Therapies Covered in the Report Include:

• HYQVIA: Shire/ Takeda

• Rozanolixizumab: UCB S.A.

• Temelimab: GeNeuro SA

• GGS-CIDP: Teijin Pharma

• Newgam: OctaPharma

• MD-1003: MedDay Pharmaceuticals

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Inflammatory Demyelinating Polyneuropathy Competitive Intelligence Analysis

4. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance

5. Chronic Inflammatory Demyelinating Polyneuropathy Disease Background and Overview

6. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey

7. Chronic Inflammatory Demyelinating Polyneuropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Chronic Inflammatory Demyelinating Polyneuropathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs

10. Key Endpoints of Chronic Inflammatory Demyelinating Polyneuropathy Treatment

11. Chronic Inflammatory Demyelinating Polyneuropathy Marketed Therapies

12. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs and Latest Therapeutic Advances

13. Chronic Inflammatory Demyelinating Polyneuropathy Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook (In US, EU5, and Japan)

16. Chronic Inflammatory Demyelinating Polyneuropathy Companies Active in the Market

17. Chronic Inflammatory Demyelinating Polyneuropathy Access and Reimbursement Overview

18. KOL Views on the Chronic Inflammatory Demyelinating Polyneuropathy Market

19. Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers

20. Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hyperkalemia Market

“Hyperkalemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hyperkalemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hyperkalemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Takeda, Sanofi, Argenx, UCB, GeNeuro, CSL, Grifols

“Delveinsight Business Research LLP”

DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Cystic Fibrosis Bronchiectasis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Non-Cystic Fibrosis Bronchiectasis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Cystic Fibrosis Bronchiectasis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Non-Cystic Fibrosis Bronchiectasis (NCFB): An Overview

Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory disorder characterized by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production, and recurrent pulmonary infections. NCFB often coexists with other respiratory conditions, such as chronic obstructive pulmonary disease.

The changes in the bronchial walls may occur due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified. Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum.

Prevalence of CF (Cystic fibrosis) is reported to be higher in males, while females surpass males in NCFB. However, the prevalence of NCFB is reported to be higher in males when aged ≥65 years. The precise prevalence of NCFB is difficult to determine because estimates vary among populations. However, studies report a prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals. (Maselli et al., 2017)

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Key Facts

• In 2022, antibiotics were the most prescribed medication across the US, followed by bronchodilators and steroids. Though the revenue will decline, antibiotics will maintain dominance among the current therapy classes throughout the study period.

• Among EU4 and the UK countries, the UK accounts for the maximum market size in 2022, while France occupies the bottom of the ladder in 2022.

• The total number of diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis in the United States was around 368,200+ cases in 2022.

• In the US, females diagnosed with Non-cystic Fibrosis Bronchiectasis are higher in number than males. In 2022, cases of Non-cystic Fibrosis Bronchiectasis among females were approximately 242,300+, while among the male population, there were approximately 125,900+ NCFB cases. These numbers are expected to rise during the study period.

• According to DelveInsight estimates, in EU4 and the UK, the prevalence of moderate cases of Non-cystic Fibrosis Bronchiectasis is the highest, followed by mild Non-cystic Fibrosis Bronchiectasis and severe Non-cystic Fibrosis Bronchiectasis cases. 

Non-Cystic Fibrosis Bronchiectasis (NCFB) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Cystic Fibrosis Bronchiectasis pipeline therapies. It also thoroughly assesses the Non-Cystic Fibrosis Bronchiectasis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Non-Cystic Fibrosis Bronchiectasis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Non-Cystic Fibrosis Bronchiectasis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Non-Cystic Fibrosis Bronchiectasis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Non-Cystic Fibrosis Bronchiectasis Epidemiology, Segmented as –

• Diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis in the 7MM

• Gender-specific cases of Non-cystic Fibrosis Bronchiectasis in the 7MM

• Severity-specific cases of Non-cystic Fibrosis Bronchiectasis in the 7MM

• Etiology-associated cases of Non-cystic Fibrosis Bronchiectasis in the 7MM

• Microbiology of Non-cystic Fibrosis Bronchiectasis patients in the 7MM

Non-Cystic Fibrosis Bronchiectasis (NCFB) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Non-Cystic Fibrosis Bronchiectasis market or expected to be launched during the study period. The analysis covers the Non-Cystic Fibrosis Bronchiectasis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Non-Cystic Fibrosis Bronchiectasis drugs based on their sale and market share.

The report also covers the Non-Cystic Fibrosis Bronchiectasis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Non-Cystic Fibrosis Bronchiectasis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Non-Cystic Fibrosis Bronchiectasis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

Non-Cystic Fibrosis Bronchiectasis (NCFB) Therapeutics Analysis

When a specific disorder is found to cause bronchiectasis, disease management should primarily be directed at the underlying cause. Non‐cystic Fibrosis Bronchiectasis management is aimed at preventing disease progression and improving quality of life by reducing symptoms and exacerbations. 

Treatment is based on breaking the vicious cycle using mucoactive treatments and airway clearance techniques (ACTs) to enhance mucus clearance, inhaled or oral antibiotic therapy to reduce chronic bronchial infection, anti-inflammatory therapies to decrease associated inflammation, bronchodilator therapy, surgery, and pulmonary rehabilitation. Many treatment options for non-CF bronchiectasis are derived from the treatment regimens developed for cystic fibrosis.

Several major pharma and biotech companies are actively engaged in developing therapies for Non‐cystic fibrosis bronchiectasis. Notably, Insmed Incorporated stands out among them, with Non‐cystic fibrosis bronchiectasis drug candidates advancing to the most advanced stage, specifically phase III of clinical trials. This emphasizes the collective efforts of these companies in addressing the medical challenges associated with Non‐cystic fibrosis bronchiectasis, with Insmed Incorporated at the forefront of clinical advancements in this therapeutic domain.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Companies Actively Working in the Therapeutics Market Include

• Insmed Incorporated

• AstraZeneca

• Zambon

• CSL Behring

• Chiesi Farmaceutici

• Boehringer Ingelheim

• Armata Pharmaceuticals

• Renovion

• Sol Aero Med

• Haisco Pharmaceutical

And Many Others

Emerging and Marketed Non-Cystic Fibrosis Bronchiectasis Therapies Covered in the Report Include:

• Brensocatib: Insmed/AstraZeneca

• Benralizumab: AstraZeneca

• HSK31858: Haisco Pharmaceutical Group Co., Ltd.

• CSL 787: CSL Behring

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Non-Cystic Fibrosis Bronchiectasis Competitive Intelligence Analysis

4. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance

5. Non-Cystic Fibrosis Bronchiectasis Disease Background and Overview

6. Non-Cystic Fibrosis Bronchiectasis Patient Journey

7. Non-Cystic Fibrosis Bronchiectasis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Non-Cystic Fibrosis Bronchiectasis Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Cystic Fibrosis Bronchiectasis Unmet Needs

10. Key Endpoints of Non-Cystic Fibrosis Bronchiectasis Treatment

11. Non-Cystic Fibrosis Bronchiectasis Marketed Therapies

12. Non-Cystic Fibrosis Bronchiectasis Emerging Drugs and Latest Therapeutic Advances

13. Non-Cystic Fibrosis Bronchiectasis Seven Major Market Analysis

14. Attribute Analysis

15. Non-Cystic Fibrosis Bronchiectasis Market Outlook (In US, EU5, and Japan)

16. Non-Cystic Fibrosis Bronchiectasis Companies Active in the Market

17. Non-Cystic Fibrosis Bronchiectasis Access and Reimbursement Overview

18. KOL Views on the Non-Cystic Fibrosis Bronchiectasis Market

19. Non-Cystic Fibrosis Bronchiectasis Market Drivers

20. Non-Cystic Fibrosis Bronchiectasis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hepatitis D Market

“Hepatitis D Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hepatitis D market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hepatitis D market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – DelveInsight | Insmed, AstraZeneca, Zambon, CSL Behring, Renovion, Armata Pharma

“Delveinsight Business Research LLP”

DelveInsight’s “Leber Congenital Amaurosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Leber Congenital Amaurosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Leber Congenital Amaurosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Leber Congenital Amaurosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Leber Congenital Amaurosis: An Overview

Leber congenital amaurosis (LCA) is a rare inherited eye disorder that causes severe vision loss at birth. The disease primarily affects the retina and is the most common cause of inherited blindness in childhood. Leber Congenital Amaurosis is inherited in an autosomal recessive manner, meaning that both parents must carry a defective gene for the condition to pass it on to children. There is a 25% chance of inheriting the two Leber Congenital Amaurosis genes (one from each parent) needed to cause the disorder.

Leber Congenital Amaurosis causes an abnormally low electrical response of the retina. An electrodiagnostic test known as an electroretinogram (ERG) is recommended to investigate how the retina works. The retina’s electrical activity is measured under different lighting conditions to determine which part of the retina is not functioning normally. This test requires the eyes to be dilated with special eye drops. A hard contact lens in each eye is also used to measure the eye’s responses to different kinds of light.

Multiple genetic mutations have been identified to cause Leber Congenital Amaurosis. Therefore, new gene therapies for Leber Congenital Amaurosis are under development. Gene therapy is currently available for Leber Congenital Amaurosis caused by two mutations in a gene called RPE65, which accounts for about 6% of Leber Congenital Amaurosis cases.

Leber Congenital Amaurosis Market Key Facts

• According to the National Organization for Rare Disorders (NORD, 2021), the prevalence of Leber congenital amaurosis (LCA) has been estimated to be 1–2 per 100,000 births.

• According to Coussa et al. (2017), Leber Congenital Amaurosis is the second most common group of inherited retinal dystrophies after retinitis pigmentosa, accounting for about 5% of all retinal dystrophies. With an estimated prevalence ranging from 1 per 33,000 to 1 per 81,000, Leber Congenital Amaurosis was reported to account for about 20% of legal blindness in children.

• As per Feldhaus et al. (2020), the most frequent mutation in Leber Congenital Amaurosis patients from the large German cohort was c.2991+1655A>G – found in 87% of patients (20/23).

• Genetic and Rare Diseases Information Center (2021) estimated that the number of people with Leber Congenital Amaurosis in the US is between 3,000 and 30,000.

• As per the American Association for Pediatric Ophthalmology & Strabismus (2022), Leber Congenital Amaurosis is rare (2–3 cases per 100,000 births); about 10–18% of all cases of congenital blindness or severely reduced vision in children are caused by Leber Congenital Amaurosis.

Leber Congenital Amaurosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Leber Congenital Amaurosis pipeline therapies. It also thoroughly assesses the Leber Congenital Amaurosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Leber Congenital Amaurosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Leber Congenital Amaurosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Leber Congenital Amaurosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Leber Congenital Amaurosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Leber Congenital Amaurosis Epidemiology, Segmented as –

• Total Prevalent cases of Leber Congenital Amaurosis in the 7MM [2019–2032]

• Total Diagnosed Prevalent cases of Leber Congenital Amaurosis in the 7MM [2019–2032]

• Gene-specific cases of Leber Congenital Amaurosis in the 7MM [2019–2032]

• Treatable cases of Leber Congenital Amaurosis in the 7MM [2019–2032]

Leber Congenital Amaurosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Leber Congenital Amaurosis market or expected to be launched during the study period. The analysis covers the Leber Congenital Amaurosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Leber Congenital Amaurosis drugs based on their sale and market share.

The report also covers the Leber Congenital Amaurosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Leber Congenital Amaurosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Leber Congenital Amaurosis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/leber-congenital-amaurosis-market

Leber Congenital Amaurosis Therapeutics Analysis

There is no approved treatment for other types of Leber Congenital Amaurosis at present, but several clinical trials are ongoing. In the meantime, treatment is focused on alleviating symptoms and optimizing remaining sight by treating the other eye conditions associated with Leber Congenital Amaurosis. 

Some people with Leber Congenital Amaurosis may also benefit from low-vision aids, including electronic, computer-based, and optical aids. Low vision aids to maximize visual function can be very useful for patients with Leber Congenital Amaurosis. Some children with Leber Congenital Amaurosis suffer from conditions affecting other parts of the body (like Joubert syndrome or Senior-Loken syndrome). They need input from various specialists coordinated by the pediatrician.

In 2017, the gene therapy Luxturna (voretigene neparvovec-rzyl) was approved by the US Food and Drug Administration (FDA) to treat children and adults with two mutations in the RPE65 gene, which includes a type of Leber Congenital Amaurosis called LCA2. Luxturna is manufactured by Spark Therapeutics.

Several major pharma and biotech companies are actively involved in the development of therapies for Leber Congenital Amaurosis. The key players involved in developing new therapies to treat Leber Congenital Amaurosis include ProQR Therapeutics, Atsena Therapeutics, and others. Notably, ProQR Therapeutics stands out among them, with Leber Congenital Amaurosis drug candidates advancing to the most advanced stage, specifically phase II/III of clinical trials.

Leber Congenital Amaurosis Companies Actively Working in the Therapeutics Market Include

• ProQR Therapeutics

• Editas Medicine

• Atsena Therapeutics

• Applied Genetic Technologies 

• IVERIC bio

• Meira GTx

And Many Others

Emerging and Marketed Leber Congenital Amaurosis Therapies Covered in the Report Include:

• Sepofarsen (QR-110): ProQR Therapeutics

• EDIT-101: Editas Medicine, Inc.

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/leber-congenital-amaurosis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Leber Congenital Amaurosis Competitive Intelligence Analysis

4. Leber Congenital Amaurosis Market Overview at a Glance

5. Leber Congenital Amaurosis Disease Background and Overview

6. Leber Congenital Amaurosis Patient Journey

7. Leber Congenital Amaurosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Leber Congenital Amaurosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Leber Congenital Amaurosis Unmet Needs

10. Key Endpoints of Leber Congenital Amaurosis Treatment

11. Leber Congenital Amaurosis Marketed Therapies

12. Leber Congenital Amaurosis Emerging Drugs and Latest Therapeutic Advances

13. Leber Congenital Amaurosis Seven Major Market Analysis

14. Attribute Analysis

15. Leber Congenital Amaurosis Market Outlook (In US, EU5, and Japan)

16. Leber Congenital Amaurosis Companies Active in the Market

17. Leber Congenital Amaurosis Access and Reimbursement Overview

18. KOL Views on the Leber Congenital Amaurosis Market

19. Leber Congenital Amaurosis Market Drivers

20. Leber Congenital Amaurosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/leber-congenital-amaurosis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Candidemia Market

“Candidemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Candidemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Candidemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leber Congenital Amaurosis Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – DelveInsight | ProQR Therapeutics, Editas Medicine, Atsena, IVERIC bio, Meira GTx

“Delveinsight Business Research LLP”

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Congestive Heart Failure market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Congestive Heart Failure drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Congestive Heart Failure treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Congestive Heart Failure: An Overview

Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is cor pulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle. 

Some people face the problem of HF when the heart has trouble pumping enough blood to support other organs in the body. Some people have a hardening and stiffening of the heart muscle themself, which blocks or reduces blood flow toward the heart. HF initially causes shortness of breath and fatigue (tiredness) and the right side may further cause fluid to build up in the feet, ankles, legs, liver, abdomen, and the veins in the neck.

Congestive Heart Failure Market Key Facts

• The total market size of Congestive Heart Failure in the 7MM was approximately USD 6,000 million in 2022 and is projected to grow during the forecast period (2023-2032).

• The expanded approval of Jardiance is anticipated to rule over Entresto and Farxiga in the HFpEF segment.

• Congestive Heart Failure cases are maximum found in the age group of 75–84 years, i.e., approximately 1.6 million in the US.

• According to secondary findings, about 1.2 million people in Germany suffer from heart failure, and HF is present in about 13–29% of all patients with acute ischemic stroke.

• Japanese men smoke cigarettes at twice the rate of American men and have higher cholesterol and higher blood pressure, yet they have about 30% the rate of heart disease as in the US.

Congestive Heart Failure Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Congestive Heart Failure pipeline therapies. It also thoroughly assesses the Congestive Heart Failure market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Congestive Heart Failure drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Congestive Heart Failure Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Congestive Heart Failure epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Congestive Heart Failure epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Congestive Heart Failure Epidemiology, Segmented as –

• Total prevalent cases of Congestive Heart Failure

• Total diagnosed prevalent cases of Congestive Heart Failure

• Gender-specific prevalence of Congestive Heart Failure

• Age-specific prevalence of Congestive Heart Failure

• New York Heart Association (NYHA) class-specific diagnosed prevalence of Congestive Heart Failure

• The diagnosed prevalence of heart failure with ejection fraction

• Diagnosed prevalence of heart failure associated with comorbidities

Congestive Heart Failure Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Congestive Heart Failure market or expected to be launched during the study period. The analysis covers the Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Congestive Heart Failure drugs based on their sale and market share.

The report also covers the Congestive Heart Failure pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Congestive Heart Failure companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Congestive Heart Failure Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/congestive-heart-failure-market

Congestive Heart Failure Companies Actively Working in the Therapeutics Market Include

Some of the key companies in the Congestive Heart Failure Market include Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company, and others. 

Emerging and Marketed Congestive Heart Failure Therapies Covered in the Report Include:

• ENTRESTO: Novartis

• JARDIANCE: Boehringer Ingelheim and Eli Lilly

• KERENDIA (finerenone): Bayer

• MOUNJARO (tirzepatide): Eli Lilly and Company

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/congestive-heart-failure-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Congestive Heart Failure Competitive Intelligence Analysis

4. Congestive Heart Failure Market Overview at a Glance

5. Congestive Heart Failure Disease Background and Overview

6. Congestive Heart Failure Patient Journey

7. Congestive Heart Failure Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Congestive Heart Failure Treatment Algorithm, Current Treatment, and Medical Practices

9. Congestive Heart Failure Unmet Needs

10. Key Endpoints of Congestive Heart Failure Treatment

11. Congestive Heart Failure Marketed Therapies

12. Congestive Heart Failure Emerging Drugs and Latest Therapeutic Advances

13. Congestive Heart Failure Seven Major Market Analysis

14. Attribute Analysis

15. Congestive Heart Failure Market Outlook (In US, EU5, and Japan)

16. Congestive Heart Failure Companies Active in the Market

17. Congestive Heart Failure Access and Reimbursement Overview

18. KOL Views on the Congestive Heart Failure Market

19. Congestive Heart Failure Market Drivers

20. Congestive Heart Failure Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/congestive-heart-failure-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

BRAF-Mutant Metastatic Melanoma Market

“BRAF-Mutant Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the BRAF-Mutant Metastatic Melanoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the BRAF-Mutant Metastatic Melanoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Congestive Heart Failure Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Otsuka, Eli Lilly, AstraZeneca, Mesoblast, Bayer, Novo Nordisk